CatalystMarker
← board

AFA

distress 2/10 · well-funded / low risk
Revenue
pre-revenue
Liquidity
$3M
Runway
1.1 yrs
Shares 1y
—

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs
  • 2026-03-18S-1/Ashelf_registration
  • 2026-02-26S-1/Ashelf_registration
  • 2026-01-13S-1/Ashelf_registration
  • 2025-12-22S-1/Ashelf_registration
  • 2025-10-30S-1/Ashelf_registration
  • 2025-09-23S-1/Ashelf_registration
  • 2025-08-29S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.